T2 Biosystems Q2 Sales Below Expectations, Sticks To Annual Guidance
T2 Biosystems Inc’s (NASDAQ:TTOO) Q2 revenue reached $5.9 million, including product revenue of $2.6 million, representing decreases of 12% Y/Y…
Gritstone’s Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
Gritstone bio Inc (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…
Why Accelerate Diagnostics Shares Are Trading Higher Today
Becton Dickinson and Co (NYSE:BDX) will sell Accelerate Diagnostics Inc’s (NASDAQ:AXDX) rapid testing solution for antibiotic resistance and susceptibility, offering results in…
Why IDEAYA Biosciences Shares Plunging Today
Earlier today, IDEAYA Biosciences Inc (NASDAQ:IDYA) reported Q2 results, and shares have plunged 30% after the update. Investors are probably reacting…
Boston Scientific Adds ‘Novel’ Technology Via This Acquisition For Interventional Oncology
Boston Scientific Corporation (NYSE:BSX) has acquired privately-held Obsidio Inc that developed the Gel Embolic Material (GEM) technology to embolize blood vessels in the…
ContraFect Cuts Workforce After Trial Setback
ContraFect Corporation (NASDAQ:CFRX) said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities…
FDA Clears Organogenesis’ Next Generation PuraPly Surgical Solution
Organogenesis Holdings Inc (NASDAQ:ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. …
Horizon Therapeutics Inks Option Agreement For Atopic Dermatitis Candidate
Q32 Bio and Horizon Therapeutics plc (NASDAQ:HZNP) entered into a collaboration and option agreement to develop ADX-914 for autoimmune diseases. ADX-914 is…
BrainStorm To File US Application For NurOwn In Amyotrophic Lateral Sclerosis
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) announced its decision to submit a marketing application to the FDA seeking approval for NurOwn for…